SS-31
Phase III TrialsAlso known as: Elamipretide, MTP-131, Bendavia
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
SS-31 (Elamipretide) is a cell-permeable tetrapeptide that targets the inner mitochondrial membrane. Research has examined its potential to improve mitochondrial function, reduce oxidative stress, and support cellular bioenergetics. It has been investigated in clinical trials for heart failure and rare mitochondrial diseases.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Cardiovascular Health
- Anti-Aging & Longevity
SS-31 selectively concentrates in the inner mitochondrial membrane where it interacts with cardiolipin, stabilizing the cristae structure and optimizing electron transport chain efficiency. Research indicates it reduces mitochondrial ROS production and may improve ATP synthesis in dysfunctional mitochondria.
Phase II/III clinical trials have evaluated SS-31 for heart failure with preserved ejection fraction (HFpEF) and Barth syndrome. Generally well-tolerated in trials. Not FDA-approved as of 2024.
Want to learn more?
Ask Research Chat about SS-31Half-Life
~2-4 hours (estimated from clinical studies)
Administration
subcutaneous injection, intravenous (clinical trials)
Legal Status (US)
Investigational drug. Research chemical outside of clinical trial settings.
39 indexed research passages
Related Peptides
P21 is a short synthetic peptide derived from humanin with modifications intended to enhance potency and stability. Research has examined its potential roles in neuroprotection, cognitive function, and cellular survival signaling, particularly in the context of Alzheimer's disease models and age-related cognitive decline.
Lemairamin is a plant-derived alkaloid (isolated as WGX-50 from Evodia lepta) studied in the context of neuroprotection and neurological aging. Research in animal models has examined its potential to protect neurons from amyloid-beta toxicity and oxidative stress, with interest in Alzheimer's disease research.
KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its potent anti-inflammatory properties, particularly in gut epithelial models and inflammatory bowel disease research.
9-ME-BC is a synthetic β-carboline alkaloid with structural similarity to naturally occurring harman compounds. Research in animal models has examined its potential neuroprotective, dopaminergic, and pro-cognitive properties, with particular interest in its ability to promote neurogenesis and dendritic growth in dopaminergic neurons.